Milestone Pharma enrolls first European patient in ReVeRA-301 Phase 3 trial of etripamil nasal spray for AFib-RVR

• Milestone Pharmaceuticals enrolled the first European patient in its Phase 3 ReVeRA-301 trial for etripamil nasal spray in AFib-RVR.
• No results were presented; the study is ongoing as enrollment moves toward about 150 treated AFib-RVR events.
• The trial tests at-home, self-administered use aimed at quickly lowering heart rate and easing symptoms to reduce reliance on hospital care.
• Milestone is pursuing a single-study sNDA pathway for AFib-RVR, leveraging the same regimen used for its FDA-approved PSVT product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090800PRIMZONEFULLFEED9842569) on October 09, 2026, and is solely responsible for the information contained therein.